Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Part of paid clinical trials in Tucson, Arizona.
- Sponsor
- BioNTech SE
- Study ID
- NCT06712355
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Extensive-stage Small-cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pumitamig — DRUGIntravenous infusion
- Atezolizumab — DRUGIntravenous infusion
- Etoposide — DRUGIntravenous infusion and capsules
- Carboplatin (or cisplatin if carboplatin is not tolerated) — DRUGIntravenous infusion
Study Details
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).
Key Dates
- Start date
- Feb 3, 2025
- Status verified
- May 2026
- Primary completion
- Dec 31, 2028
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 621 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Stage 1 Control Arm - Atezolizumab + Etoposide + Carboplatin
- Experimental: Stage 1 Treatment Arm 1 - Pumitamig Dose 1 + Etoposide + Carboplatin
- Experimental: Stage 1 Treatment Arm 2 - Pumitamig Dose 2 + Etoposide + Carboplatin
- Active Comparator: Stage 2 Control Arm - Atezolizumab + Etoposide + Carboplatin
- Experimental: Stage 2 Treatment Arm - Pumitamig Dose 3 + Etoposide + Carboplatin
Primary Outcome Measure
Overall survival (OS) [ Time Frame: Up to approximately 46 months ]
Central Contacts
- BioNTech clinical trials patient information+49 6131 9084
Locations (32)
Find similar trials in Tucson, AZ
Related Studies
- Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)PHASE2 · Recruiting · University of Chicago · Chicago, Illinois
- A Study of Valemetostat in Combination With Atezolizumab in People With Lung CancerPHASE1 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver MetastasesPHASE2 · Recruiting · Kamya Sankar · Los Angeles, California
- A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCPHASE2 · Not Yet Recruiting · Jazz Pharmaceuticals · Los Angeles, California